X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1660) 1660
Publication (205) 205
Book Review (10) 10
Book Chapter (7) 7
Conference Proceeding (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1043) 1043
index medicus (891) 891
animals (831) 831
urothelium - drug effects (702) 702
female (653) 653
male (632) 632
urothelium (586) 586
urothelium - pathology (543) 543
urothelium - metabolism (442) 442
urology & nephrology (431) 431
urinary bladder - drug effects (360) 360
rats (334) 334
cancer (325) 325
middle aged (320) 320
bladder (314) 314
aged (294) 294
oncology (278) 278
mice (268) 268
bladder cancer (258) 258
urothelium - cytology (245) 245
urinary bladder - metabolism (238) 238
urinary bladder neoplasms - pathology (236) 236
expression (220) 220
adult (217) 217
urinary bladder (215) 215
urinary bladder neoplasms - drug therapy (208) 208
chemotherapy (204) 204
urinary-bladder (189) 189
urology (186) 186
pharmacology & pharmacy (182) 182
cells, cultured (164) 164
urinary bladder - pathology (162) 162
bladder-cancer (157) 157
research (152) 152
toxicology (151) 151
treatment outcome (150) 150
dose-response relationship, drug (149) 149
cell line (147) 147
immunohistochemistry (139) 139
rats, sprague-dawley (135) 135
cells (133) 133
aged, 80 and over (132) 132
carcinoma (131) 131
time factors (129) 129
interstitial cystitis (124) 124
urothelium - physiology (123) 123
cell biology (121) 121
article (120) 120
care and treatment (120) 120
medicine (119) 119
in-vitro (118) 118
cisplatin (115) 115
analysis (112) 112
apoptosis (109) 109
cell line, tumor (107) 107
research article (107) 107
carcinoma, transitional cell - drug therapy (106) 106
physiology (103) 103
transitional-cell carcinoma (103) 103
urinary bladder - physiology (103) 103
antineoplastic combined chemotherapy protocols - therapeutic use (102) 102
administration, intravesical (101) 101
health aspects (100) 100
urologic neoplasms - drug therapy (98) 98
urothelial carcinoma (97) 97
gene expression (94) 94
urinary bladder neoplasms - metabolism (92) 92
urinary bladder - cytology (91) 91
pathology (90) 90
tumors (90) 90
urologic and male genital diseases (90) 90
multidisciplinary sciences (89) 89
urologic neoplasms - pathology (89) 89
disease models, animal (86) 86
proteins (86) 86
urine (86) 86
gemcitabine (85) 85
rat (85) 85
inflammation (84) 84
muscle contraction - drug effects (84) 84
urinary bladder neoplasms - genetics (84) 84
physiological aspects (82) 82
in vitro techniques (81) 81
overactive bladder (81) 81
risk factors (80) 80
signal transduction (80) 80
therapy (80) 80
methotrexate (79) 79
medicine, research & experimental (78) 78
muscle, smooth - drug effects (78) 78
carcinoma, transitional cell - pathology (77) 77
deoxycytidine - analogs & derivatives (77) 77
mice, inbred c57bl (77) 77
rats, wistar (77) 77
activation (76) 76
cell proliferation - drug effects (76) 76
biochemistry & molecular biology (75) 75
toxicity (75) 75
apoptosis - drug effects (74) 74
doxorubicin (74) 74
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1631) 1631
Russian (13) 13
German (6) 6
Japanese (3) 3
Chinese (2) 2
French (2) 2
Italian (2) 2
Polish (2) 2
Hebrew (1) 1
Hungarian (1) 1
Spanish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 02/2018, Volume 554, Issue 7693, pp. 544 - 548
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients... 
METASTATIC MELANOMA | CTLA-4 BLOCKADE | BLADDER-CANCER | THERAPY | LANDSCAPE | SUBTYPES | UROTHELIAL CARCINOMA | MULTIDISCIPLINARY SCIENCES | GENES | ADAPTIVE IMMUNE RESISTANCE | MPDL3280A | CD8-Positive T-Lymphocytes - cytology | Humans | Antibodies, Monoclonal - therapeutic use | Urothelium - pathology | Urologic Neoplasms - pathology | Neoplasm Metastasis | Urologic Neoplasms - drug therapy | Urologic Neoplasms - genetics | Immunotherapy | Antibodies - immunology | Antigens, Neoplasm - metabolism | Transforming Growth Factor beta - antagonists & inhibitors | Antigens, Neoplasm - analysis | Disease Models, Animal | Fibroblasts - metabolism | Antibodies - therapeutic use | Antigens, Neoplasm - immunology | Antibodies, Monoclonal - pharmacology | Treatment Outcome | B7-H1 Antigen - immunology | Urologic Neoplasms - immunology | Antibodies - pharmacology | Tumor Microenvironment - immunology | Collagen - metabolism | Phenotype | Animals | B7-H1 Antigen - antagonists & inhibitors | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | CD8-Positive T-Lymphocytes - drug effects | Urothelium - immunology | Mice | Mutation | CD8-Positive T-Lymphocytes - immunology | Urothelium - drug effects | Transforming Growth Factor beta - metabolism | Cohort Studies | Drug Resistance, Neoplasm - drug effects | PD-1 protein | CD8 antigen | Transforming growth factor-a | Antibodies | Parenchyma | Lymphocytes T | Metastasis | Immunity | Metastases | Genotype & phenotype | Signal transduction | Lymphocytes | Cell cycle | Fibroblasts | Growth factors | Urothelial cancer | Phenotypes | Cytokines | Melanoma | Blocking | Gene expression | Patients | Generalized linear models | Signaling | Stromal cells | Medical prognosis | Collagen | PD-L1 protein | Ligands | Determinants | Infiltration | Cancer | Tumors | Apoptosis | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Journal of Urology, ISSN 0022-5347, 2005, Volume 174, Issue 3, pp. 977 - 983
Journal Article
Nature Neuroscience, ISSN 1097-6256, 09/2002, Volume 5, Issue 9, pp. 856 - 860
In the urinary bladder, the capsaicin-gated ion channel TRPV1 is expressed both within afferent nerve terminals and within the epithelial cells that line the... 
CELLS | PAIN | RAT | CHANNEL | REFLEX | RESINIFERATOXIN | INTRAVESICAL CAPSAICIN | RELEASE | ATP | NEUROSCIENCES | Immunohistochemistry | Reflex - genetics | Spinal Cord - metabolism | Capsaicin - pharmacology | Muscle Contraction - genetics | Receptors, Drug - genetics | Reflex - drug effects | Urination - genetics | Male | Urinary Bladder - innervation | Urothelium - pathology | Muscle, Smooth - drug effects | Adenosine Triphosphate - metabolism | Urination - drug effects | Receptors, Drug - deficiency | Spinal Cord - cytology | Urothelium - ultrastructure | Mechanoreceptors - metabolism | Urothelium - innervation | Neurons, Afferent - drug effects | Physical Stimulation | Muscle, Smooth - innervation | Cells, Cultured | Proto-Oncogene Proteins c-fos - metabolism | Acetic Acid - pharmacology | Microscopy, Electron | Mice, Knockout | Animals | Receptors, Drug - drug effects | Visceral Afferents - metabolism | Mechanoreceptors - drug effects | Muscle Contraction - drug effects | Muscle, Smooth - physiopathology | Urinary Bladder - physiopathology | Signal Transduction - physiology | Urinary Bladder - drug effects | Mice | Spinal Cord - physiopathology | Visceral Afferents - drug effects | Neurons, Afferent - metabolism | Nitric Oxide - metabolism | Bladder | Physiological aspects | Genetic aspects | Ion channels | Research | Neurons
Journal Article
Journal Article
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 51 - 64
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2017, Volume 23, Issue 14, pp. 3610 - 3618
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 769 - 776
Summary Background No standard treatment exists for patients with platinum-refractory urothelial cancer. Taxanes and vinflunine are commonly used, but response... 
Hematology, Oncology and Palliative Medicine | SPARC | CISPLATIN | ONCOLOGY | NAB-PACLITAXEL | TRANSITIONAL-CELL CARCINOMA | RANDOMIZED-TRIAL | OPEN-LABEL | II TRIAL | CANCER | DOCETAXEL | GEMCITABINE | Albumins - chemistry | Albumin-Bound Paclitaxel | Humans | Middle Aged | Ureteral Neoplasms - pathology | Male | Drug Carriers - chemistry | Urothelium - pathology | Nanoparticles | Ureteral Neoplasms - drug therapy | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Albumins - adverse effects | Time Factors | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | Adult | Female | Paclitaxel - administration & dosage | Antineoplastic Agents, Phytogenic - adverse effects | Carcinoma - secondary | Carcinoma - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Paclitaxel - adverse effects | Albumins - administration & dosage | Antineoplastic Agents, Phytogenic - chemistry | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Chemistry, Pharmaceutical | Canada | Disease-Free Survival | Administration, Intravenous | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Urothelium - drug effects | Antimitotic agents | Care and treatment | Albumin | Metastasis | Drug therapy | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Tissue Engineering - Part A, ISSN 1937-3341, 05/2010, Volume 16, Issue 5, pp. 1769 - 1779
Journal Article
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 76 - 86
Summary Background Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival after cystectomy. The EORTC 30994 trial aimed to... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | PLUS CISPLATIN | METAANALYSIS | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | DOXORUBICIN | METHOTREXATE | VINBLASTINE | CANCER | GEMCITABINE | Lymph Node Excision | Cystectomy - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Male | Vinblastine - administration & dosage | Cystectomy - adverse effects | Urothelium - pathology | Cisplatin - administration & dosage | Time Factors | Urinary Bladder Neoplasms - pathology | Female | Chemotherapy, Adjuvant | Carcinoma - pathology | Doxorubicin - administration & dosage | Carcinoma - drug therapy | Urinary Bladder Neoplasms - mortality | Drug Administration Schedule | Time-to-Treatment | Carcinoma - surgery | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Urinary Bladder Neoplasms - surgery | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Methotrexate - administration & dosage | Urothelium - surgery | Neoplasm Staging | Urothelium - drug effects | Deoxycytidine - analogs & derivatives | Care and treatment | Chemotherapy | Carcinoma | Hospitals | Cancer
Journal Article
Biomaterials, ISSN 0142-9612, 2010, Volume 31, Issue 24, pp. 6207 - 6217
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2014, Volume 9, Issue 2, p. e89806
Conventional adjuvant chemotherapies for bladder transitional cell carcinomas (TCCs) may cause strong systemic toxicity and local irritation. Non-toxic... 
SURVIVAL | INTRAVESICAL CHEMOTHERAPY | ACTIVATION | CISPLATIN | PATHWAY | MITOMYCIN-C | MULTIDISCIPLINARY SCIENCES | DOWN-REGULATION | GRADE | EXPRESSION | MEDULLOBLASTOMA | Immunohistochemistry | Stilbenes - therapeutic use | Apoptosis - drug effects | Humans | DNA Primers - genetics | Stilbenes - pharmacology | Dose-Response Relationship, Drug | Flow Cytometry | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | STAT3 Transcription Factor - metabolism | Urinary Bladder Neoplasms - drug therapy | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Animals | Analysis of Variance | Mice, Nude | Active Transport, Cell Nucleus - drug effects | Carcinoma, Transitional Cell - drug therapy | Fluorescent Antibody Technique | Cell Line, Tumor | Tyrphostins | Cell Proliferation - drug effects | Mice | S Phase Cell Cycle Checkpoints - drug effects | Chemotherapy | Growth | Resveratrol | Tumor proteins | Vascular endothelial growth factor | Bladder cancer | Apoptosis | Cancer | Short term | p53 Protein | Brain cancer | c-Myc protein | Nuclear engineering | Transitional cell carcinoma | Inactivation | Cancer therapies | Cell growth | Urinary bladder | Janus kinase 2 | Biocompatibility | Drug dosages | Medical research | Survivin | Metabolism | Gene expression | SIRT1 protein | Nuclear safety | Urothelium | Oxidative stress | Animal models | Phosphorylation | Transcription | Laboratories | Toxicity | Gene regulation | Bladder | Biology | Myc protein | Rodents | Xenografts | Cell cycle | Safety | Irritation | Translocation | Deactivation | Stat3 protein | Feasibility studies | Nuclear transport | Signaling | S phase | Tumors
Journal Article